VBI-2905 is under clinical development by VBI Vaccines and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VBI-2905’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VBI-2905 overview

VBI-2905 is under development for the prevention of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.351 strain. The vaccine is a monovalent enveloped virus like particle (eVLP) candidate expressing the pre-fusion form of the spike protein from the B.1.351 strain (also known as 501Y.V2). It is administered by intramuscular route.

VBI Vaccines overview

VBI Vaccines (VBI), a subsidiary of FDS Pharma LLP is a biopharmaceutical company that discovers and develops novel vaccines in the therapeutic areas of immuno-oncology and infectious diseases. The company’s pipeline products include PreHevbrio for the treatment of Hepatitis B (HBV); VBI-1501 treats Cytomegalovirus (CMV); VBI-2902 targets COVID-19; VBI-2905 is for the treatment of COVID-19 (Beta Variant); VBI-2901 treats Coronaviruses; VBI-2501 targets Zika; VBI-2601 (BRII-179) for Hepatitis B (HBV); VBI-1901 treats Glioblastoma (GBM). The company operates through its research facilities located in Ottawa, Canada and a manufacturing facility in Rehovot, Israel. VBI is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of VBI-2905’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.